Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Antagon
2. Ganirelix
3. Ganirelix Diacetate
4. Gnrh, N-ac-2-nal(1)-4-cl-phe(2)-3-pal(3)-et2-harg(6,8)-alanh2(10)-
5. Lhrh, N-acetyl-2-naphthylalanyl(1)-(4-chlorophenylalanyl)(2)-3-pyrdinylalanyl(3)-diethylhomoarginyl(6,8)-alaninamide(10)-
6. Lhrh,n-ac-2-nal(1)-4-cl-phe(2)-3-pal(3)-et2-harg(6,8)-alanh2(10)-
7. N-ac-(2-naphthyl)ala-2-(4-cl-phe)-3-(3-pyridinyl-ala)-6,8-et2-harg-10-alanh2-lhrh
8. N-acetyl-3-(2-naphthyl)-d-alanyl-p-chloro-d-phenylalanyl-3-(3-pyridyl)-d-alanyl-l-seryl-l-tyrosyl-n(sup 6)-(n,n'-diethylamidino)-d-lysyl-l-leucyl-n(sup 6)-(n,n'-diethylamidino)-l-lysyl-l-prolyl-d-alaninamide Diacetate (salt)
9. Orgalutran
10. Rs 26306
11. Rs-26306
12. Rs-26306-298
1. 129311-55-3
2. Ganirelix Acetate [usan]
3. Ganirelix Acetate Injection
4. Antagon
5. 56u7906fqw
6. Orgalutran
7. Rs-26306
8. Ganirelix (acetate)
9. Ganirest
10. D-alaninamide,n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-[bis(ethylamino)methylene]-d-lysyl-l-leucyl-n6-[bis(ethylamino)methylene]-l-lysyl-l-prolyl-, Diacetate (salt)
11. N-acetyl-3-(2-naphthyl)-d-alanyl-p-chloro-d-phenylalanyl-3-(3-pyridyl)-d-alanyl-l-seryl-l-tyrosyl-n(sup 6)-(n,n'-diethylamidino)-d-lysyl-l-leucyl-n(sup 6)-(n,n'-diethylamidino)-l-lysyl-l-prolyl-d-alaninamide Diacetate (salt)
12. Rs-26306-298
13. Unii-56u7906fqw
14. Ganirest (tn)
15. Orgalutran Tfa Salt
16. Ganirelix Acetate [mi]
17. Ganirelix Acetate (jan/usan)
18. Ganirelix Acetate [jan]
19. Org-37462
20. Ganirelix Acetate [vandf]
21. Ganirelix Acetate Injection (tn)
22. Ganirelix Acetate [mart.]
23. Ganirelix Acetate [who-dd]
24. Akos025394292
25. Ganirelix Acetate [orange Book]
26. Hy-109532
27. D04302
28. 311g553
29. J-005666
30. Q27261435
31. D-alaninamide, N-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n(sup 6)-((ethylamino)(ethylimino)methyl)-d-lysyl-l-leucyl-n(sup 6)-((ethylamino)(ethylimino)methyl)-l-lysyl-l-prolyl-, Diacetate (salt)
| Molecular Weight | 1690.4 g/mol |
|---|---|
| Molecular Formula | C84H121ClN18O17 |
| Hydrogen Bond Donor Count | 18 |
| Hydrogen Bond Acceptor Count | 20 |
| Rotatable Bond Count | 48 |
| Exact Mass | 1688.8845622 g/mol |
| Monoisotopic Mass | 1688.8845622 g/mol |
| Topological Polar Surface Area | 526 Ų |
| Heavy Atom Count | 120 |
| Formal Charge | 0 |
| Complexity | 3060 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 2 | |
|---|---|
| Drug Name | Ganirelix acetate |
| Drug Label | Ganirelix Acetate Injection is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix Acetate is derived from native GnRH with substitutions of amino acids at positions 1,... |
| Active Ingredient | Ganirelix acetate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 250mcg base/0.5ml |
| Market Status | Prescription |
| Company | Organon Usa |
| 2 of 2 | |
|---|---|
| Drug Name | Ganirelix acetate |
| Drug Label | Ganirelix Acetate Injection is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix Acetate is derived from native GnRH with substitutions of amino acids at positions 1,... |
| Active Ingredient | Ganirelix acetate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 250mcg base/0.5ml |
| Market Status | Prescription |
| Company | Organon Usa |
The prevention of premature luteinising-hormone surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction techniques.
In clinical studies, Orgalutran was used with recombinant human follicle-stimulating hormone or corifollitropin alfa, the sustained follicle stimulant.
Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).
Hormone Antagonists
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)
H01CC01
H01CC01
GDUFA
DMF Review : Complete
Rev. Date : 2024-03-07
Pay. Date : 2024-03-05
DMF Number : 13971
Submission : 1999-02-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40573
Submission : 2024-10-17
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36902
Submission : 2022-04-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2021-08-30
Pay. Date : 2021-07-13
DMF Number : 36108
Submission : 2021-07-14
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2016-02-04
Pay. Date : 2015-09-18
DMF Number : 29585
Submission : 2015-07-24
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2020-05-07
Pay. Date : 2020-04-15
DMF Number : 33546
Submission : 2019-12-13
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-08-04
Pay. Date : 2017-07-27
DMF Number : 30800
Submission : 2016-07-28
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25866
Submission : 2012-03-28
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39994
Submission : 2024-05-29
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2025-10-01
Valid Till : 2028-06-10
Written Confirmation Number : WC-0443
Address of the Firm : 4th Floor, Survey No. 71 & 72,Indrakaran (Village), Kandi (Mandal), Sangareddy (...

Date of Issue : 2022-06-08
Valid Till : 2025-07-25
Written Confirmation Number : WC-0159nA2
Address of the Firm : A-7/A-8, M.I.D.C Industrial Area, Ahmednagar-414111, Maharashtra, India

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ganirelix Acetate-Generic is a synthetic decapeptide used to prevent premature LH surges during controlled ovarian hyperstimulation.
Lead Product(s): Ganirelix,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Ganirelix Acetate-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ganirelix,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin launches Ganirelix Acetate Injection in US
Details : Ganirelix Acetate-Generic is a synthetic decapeptide used to prevent premature LH surges during controlled ovarian hyperstimulation.
Product Name : Ganirelix Acetate-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GenSci094 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility.
Lead Product(s): GenSci094,Follitropin Alfa,Ganirelix,Human Chorionic Gonadotropin,Progesterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GenSci094,Follitropin Alfa,Ganirelix,Human Chorionic Gonadotropin,Progesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sixth Affiliated Hospital, Sun Yat-sen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GenSci094 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 19, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SHR7280 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility, Female.
Lead Product(s): SHR7280,Ganirelix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SHR7280,Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SHR7280 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility, Female.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 16, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Lead Product(s): Ganirelix,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Antagonä-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ganirelix,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment
Details : Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Product Name : Antagonä-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2023

Details:
Follitropin Beta is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Infertility.
Lead Product(s): Follitropin Beta,Ganirelix,Delta-(L-Alpha-Aminoadipoyl)-L-Cysteinyl-Glycine,Estradiol Valerate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Hormone
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2017

Lead Product(s) : Follitropin Beta,Ganirelix,Delta-(L-Alpha-Aminoadipoyl)-L-Cysteinyl-Glycine,Estradiol Valerate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Follitropin Beta is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
October 03, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ganirelix Acetate is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility.
Lead Product(s): Ganirelix,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 13, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ganirelix,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ganirelix Acetate is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 13, 2017

Details:
Follitropin Beta is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Infertility.
Lead Product(s): Follitropin Beta,Ganirelix,Gonadorelin,Triptorelin Pamoate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Hormone
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 21, 2015

Lead Product(s) : Follitropin Beta,Ganirelix,Gonadorelin,Triptorelin Pamoate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Follitropin Beta is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 21, 2015

Details:
Ganirelix Acetate is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diminished Ovarian Reserve.
Lead Product(s): Ganirelix,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Protein
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 07, 2012

Lead Product(s) : Ganirelix,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Delayed Start to Ovarian Stimulation
Details : Ganirelix Acetate is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diminished Ovarian Reserve.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 07, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
MK-8962 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility.
Lead Product(s): MK-8962,Recombinant Follicle Stimulating Hormone,Ganirelix,Human Chorionic Gonadotropin,Progesterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MK-8962,Recombinant Follicle Stimulating Hormone,Ganirelix,Human Chorionic Gonadotropin,Progesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MK-8962 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 16, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ganirelix is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Lead Product(s): Ganirelix,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Maureen Kelly
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ganirelix,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Maureen Kelly
Deal Size : Inapplicable
Deal Type : Inapplicable
A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs
Details : Ganirelix is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2011

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
87
PharmaCompass offers a list of Ganirelix API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ganirelix manufacturer or Ganirelix supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ganirelix manufacturer or Ganirelix supplier.
PharmaCompass also assists you with knowing the Ganirelix API Price utilized in the formulation of products. Ganirelix API Price is not always fixed or binding as the Ganirelix Price is obtained through a variety of data sources. The Ganirelix Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ganirelix manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ganirelix, including repackagers and relabelers. The FDA regulates Ganirelix manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ganirelix API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ganirelix manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ganirelix supplier is an individual or a company that provides Ganirelix active pharmaceutical ingredient (API) or Ganirelix finished formulations upon request. The Ganirelix suppliers may include Ganirelix API manufacturers, exporters, distributors and traders.
click here to find a list of Ganirelix suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ganirelix DMF (Drug Master File) is a document detailing the whole manufacturing process of Ganirelix active pharmaceutical ingredient (API) in detail. Different forms of Ganirelix DMFs exist exist since differing nations have different regulations, such as Ganirelix USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ganirelix DMF submitted to regulatory agencies in the US is known as a USDMF. Ganirelix USDMF includes data on Ganirelix's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ganirelix USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ganirelix suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ganirelix Drug Master File in Korea (Ganirelix KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ganirelix. The MFDS reviews the Ganirelix KDMF as part of the drug registration process and uses the information provided in the Ganirelix KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ganirelix KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ganirelix API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ganirelix suppliers with KDMF on PharmaCompass.
A Ganirelix written confirmation (Ganirelix WC) is an official document issued by a regulatory agency to a Ganirelix manufacturer, verifying that the manufacturing facility of a Ganirelix active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ganirelix APIs or Ganirelix finished pharmaceutical products to another nation, regulatory agencies frequently require a Ganirelix WC (written confirmation) as part of the regulatory process.
click here to find a list of Ganirelix suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ganirelix as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ganirelix API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ganirelix as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ganirelix and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ganirelix NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ganirelix suppliers with NDC on PharmaCompass.
Ganirelix Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ganirelix GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ganirelix GMP manufacturer or Ganirelix GMP API supplier for your needs.
A Ganirelix CoA (Certificate of Analysis) is a formal document that attests to Ganirelix's compliance with Ganirelix specifications and serves as a tool for batch-level quality control.
Ganirelix CoA mostly includes findings from lab analyses of a specific batch. For each Ganirelix CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ganirelix may be tested according to a variety of international standards, such as European Pharmacopoeia (Ganirelix EP), Ganirelix JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ganirelix USP).